A new Schrödinger-backed start­up emerges from the sci­en­tist who mapped the first hu­man GPCR

One of the most pop­u­lar tar­gets in drug de­vel­op­ment, rep­re­sent­ing about a third of ex­ist­ing drugs, are G-pro­tein cou­pled re­cep­tors — the tiny but in­te­gral mem­brane …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER